Navigation Links
Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Date:10/5/2009

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced the appointment of Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, Inc. (Nasdaq: ZGEN), to its board of directors.

"We are pleased to welcome Doug to our board of directors and look forward to the contributions he will make to Oncothyreon. His extensive experience in drug development, research and operations will be invaluable," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon.

Dr. Williams joined ZymoGenetics in 2004 and has served as a director and Chief Executive Officer since January 2009. He has held senior level positions at a number of prominent biotechnology companies, including Seattle Genetics, Inc., Immunex Corporation, and Amgen, Inc. As Executive Vice President and Chief Technology Officer at Immunex, Dr. Williams played a significant role in the discovery and early development of Enbrel, the first biologic approved for the treatment of rheumatoid arthritis. Dr. Williams currently serves as a director of Array BioPharma Inc. and Aerovance, Inc. Dr. Williams received a B.S. (magna cum laude) in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Cancer Institute Division.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
2. Oncothyreon reports second quarter 2009 financial results
3. Oncothyreon announces closing of $15.0 million registered direct financing
4. Oncothyreon announces webcast of second quarter 2009 financial results conference call
5. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
6. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
7. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
8. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
9. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Oncothyreon announces closing of $11.1 million registered direct financing
11. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Point, IA (PRWEB) , ... January 17, 2017 ... ... from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance System ... to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean herbicide. ...
(Date:1/17/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... earnings conference call will be broadcast live over the ... Eastern Time.  A news release detailing the quarterly and ... Eastern Time the morning of the conference call. ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent ... patients over profits, while only 16 percent believe health ... released today. Meanwhile, 36 percent of U.S. adults believe ... patients over profits, compared to hospitals (23%). ... maelstrom," said Wendy Salomon , vice president of ...
(Date:1/17/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... of the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment ... be validating these new tools and assays, and their applicability in drug safety ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
Breaking Biology News(10 mins):